

HOLLIS EDEN PHARMACEUTICALS INC /DE/  
Form 8-K  
September 26, 2003

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**  
**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2003

**HOLLIS-EDEN PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**000-24672**  
(Commission File No.)

**13-3697002**  
(IRS Employer Identification No.)

**4435 Eastgate Mall, Suite 400**

**San Diego, California 92121**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(858) 587-9333**

**Item 5. Other Events and Required FD Disclosure.**

On September 26, 2003, Hollis-Eden Pharmaceuticals, Inc. (the Company ) announced the pricing of its follow-on offering of 2,500,000 million shares of its common stock at \$25.00 per share. A copy of the Company's press release, dated September 26, 2003, relating to the offering is attached hereto as Exhibit 99.1.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

**(c) Exhibits.**

<b>Number</b>	<b>Description</b>
99.1	Press release issued by the Company on September 26, 2003.



**INDEX TO EXHIBITS**

99.1 Press release issued by the Company on September 26, 2003.